Jeff Yass’s Trevi Therapeutics TRVI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.9M Buy
342,415
+319,065
+1,366% +$5.49M ﹤0.01% 4476
2026
Q2
$435K Sell
23,350
-204,338
-90% -$2.97M ﹤0.01% 10223
2026
Q1
$2.72M Sell
227,688
-597,860
-72% -$6.69M ﹤0.01% 5483
2025
Q4
$10.3M Sell
825,548
-775,194
-48% -$8.96M ﹤0.01% 2999
2025
Q3
$14.6M Buy
1,600,742
+1,473,157
+1,155% +$11M ﹤0.01% 2528
2025
Q2
$698K Sell
127,585
-153,514
-55% -$955K ﹤0.01% 8361
2025
Q1
$1.77M Buy
281,099
+240,491
+592% +$1.15M ﹤0.01% 5806
2024
Q4
$167K Buy
40,608
+230
+0.6% +$736 ﹤0.01% 10923
2024
Q3
$135K Buy
+40,378
New +$120K ﹤0.01% 10837
2024
Q1
– Sell
-17,207
Closed -$23.1K – 13345
2023
Q4
$23.1K Buy
+17,207
New +$26.1K ﹤0.01% 11947
2023
Q3
– Sell
-11,571
Closed -$27.7K – 13007
2023
Q2
$27.7K Sell
11,571
-16,095
-58% -$40.6K ﹤0.01% 11548
2023
Q1
$51.2K Buy
+27,666
New +$62.6K ﹤0.01% 11695
2021
Q1
– Sell
-14,828
Closed -$36K – 12869
2020
Q4
$36K Buy
+14,828
New +$48K ﹤0.01% 10816

Other funds holding TRVI

Jeff Yass's TRVI Position: Q3 2026 in Review

Jeff Yass increased its Trevi Therapeutics (TRVI) stake by 1,366% in Q3 2026, buying an estimated $5.49M and bringing the position to 342,415 shares worth $4.9M. The position accounts for ﹤0.01% of the portfolio, ranked #4476.

Jeff Yass first reported a position in TRVI in Q4 2020 and has held it in 13 quarters since. The position peaked at $14.6M in Q3 2025. 223 funds tracked by Wall St. Rank hold TRVI as of Q3 2026.

  • Jeff Yass held 342,415 shares of Trevi Therapeutics worth $4.9M as of Q3 2026.
  • Jeff Yass bought 319,065 Trevi Therapeutics shares in Q3 2026, an estimated $5.49M.
  • Trevi Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #4476 holding.
  • Jeff Yass first reported a position in Trevi Therapeutics in Q4 2020 and has held it in 13 quarters since.
  • Jeff Yass's Trevi Therapeutics position peaked at $14.6M in Q3 2025.
  • 223 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.